We investigated the potential role of pivmecillinam in the treatment of urinary tract infections in children. Among 351 children (0–6 years) with urinary tract infections, 83% could be treated with pivmecillinam following urine culture. Resistance was highest in infants (0–3 months) caused by the high prevalence of Enterococcus faecalis . This result emphasizes the necessity for developing a pediatric oral form of pivmecillinam.
No takes yet. Share an insight, caveat, or question.
Andersen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: